— Experts outline three better ways to use limited resources by Molly Walker The resources used to implement a "boosters for all" COVID-19 strategy may be better invested in promoting initial vaccine uptake or increasing access to rapid testing, experts argued....
— Study shows importance of vaccination to prevent severe disease, even among previously infected by Molly Walker n people hospitalized for COVID-like respiratory illnesses, unvaccinated adults who previously had COVID-19 were over five times more likely to test...
— Moderna, Johnson & Johnson boosters also get thumbs up by Molly Walker The FDA authorized booster doses of Moderna and Johnson & Johnson's COVID-19 vaccines and also authorized a "mix and match" or heterologous approach to boosters for all three available...
— Researchers urge caution, but a clearer picture starts to emerge by Molly Walker A so-called "mix and match" COVID vaccine series using a different booster than the primary series was safe and produced an increase in immune response comparable to or greater than...
— But enrollment halted early, and few patients were actually hospitalized by Molly Walker Remdesivir (Veklury) reduced risk of hospitalizations by 87% compared with placebo in outpatients at high risk of progression to severe COVID-19, a researcher said. While the...
— Advisors overwhelmingly support authorization, but shot down full approval bid by Molly Walker An FDA advisory panel recommended emergency use authorization (EUA) of a booster dose of the Pfizer/BioNTech COVID-19 vaccine (Comirnaty) for individuals 65 and older, and...
— "If you have had COVID-19 before, please still get vaccinated," says CDC Director by Molly Walker Unvaccinated adults who were previously infected with COVID-19 were twice as likely to be reinfected as those previously infected but also fully vaccinated, researchers...
REGEN-COV becomes first monoclonal antibody treatment with EUA following exposure alone By Molly Walker FDA expanded the emergency use authorization (EUA) for the monoclonal antibody cocktail casirivimab and imdevimab, to include post-exposure prophylaxis (PEP) among...